Home › NCT05189808
Radiofrequency Ablation for BIII Thyroid Nodules
Radiofrequency Ablation for Indeterminate Bethesda III Thyroid Nodules
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Indeterminate Bethesda III nodules that have been molecularly profiled benign with either Afirma Genomic Sequencing Classifier (GSC) or ThyroSeq v3 tests Exclusion Criteria: * cardiac arrthymias * pregnancy
About the study
The purpose of this observational chart review study is to evaluate the efficacy and safety of Radiofrequency Ablation (RFA) for treatment of indeterminate thyroid nodules before and after RFA procedure. This is a data collection study in which the investigators ask patients to give access to information generated before and after RFA treatment of their condition. The RFA procedure uses image guidance to place an electrode through the skin into the target area. In RFA, high-frequency electrical currents are passed through an electrode, creating a small region of heat to treat the lesion.
What is being tested
- Radiofrequency Ablation (procedure)
Sponsor: Columbia University · Participants: 50 · Started: Aug 1, 2020
Contact the study team
- Jennifer H Kuo, MD MS · Phone: 212-305-6969
- Catherine McManus, MD MS · Phone: 212-305-6969
Official record on ClinicalTrials.gov — NCT05189808
Locations in the U.S.
| New York | Columbia University, New York |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.